Talbot GH - Search Results

1

What is in the pipeline for Gram-negative pathogens?

Talbot GH. Talbot GH. Expert Rev Anti Infect Ther. 2008 Feb;6(1):39-49. doi: 10.1586/14787210.6.1.39. Expert Rev Anti Infect Ther. 2008. PMID: 18251663 Review.

2

The antibiotic development pipeline for multidrug‐resistant gram‐negative bacilli: current and future landscapes.

Talbot GH. Talbot GH. Infect Control Hosp Epidemiol. 2010 Nov;31 Suppl 1:S55-8. doi: 10.1086/655988. Infect Control Hosp Epidemiol. 2010. PMID: 20929372 Review.

3

In vitro profiling of ceftaroline against a collection of recent bacterial clinical isolates from across the United States.

Ge Y, Biek D, Talbot GH, Sahm DF. Ge Y, et al. Among authors: talbot gh. Antimicrob Agents Chemother. 2008 Sep;52(9):3398-407. doi: 10.1128/AAC.00149-08. Epub 2008 Jul 14. Antimicrob Agents Chemother. 2008. PMID: 18625769 Free PMC article.

4

10 x '20 Progress--development of new drugs active against gram-negative bacilli: an update from the Infectious Diseases Society of America.

Boucher HW, Talbot GH, Benjamin DK Jr, Bradley J, Guidos RJ, Jones RN, Murray BE, Bonomo RA, Gilbert D; Infectious Diseases Society of America. Boucher HW, et al. Among authors: talbot gh. Clin Infect Dis. 2013 Jun;56(12):1685-94. doi: 10.1093/cid/cit152. Epub 2013 Apr 17. Clin Infect Dis. 2013. PMID: 23599308 Free PMC article.

5

Progress in the Fight Against Multidrug-Resistant Bacteria 2005-2016: Modern Noninferiority Trial Designs Enable Antibiotic Development in Advance of Epidemic Bacterial Resistance.

Rex JH, Talbot GH, Goldberger MJ, Eisenstein BI, Echols RM, Tomayko JF, Dudley MN, Dane A. Rex JH, et al. Among authors: talbot gh. Clin Infect Dis. 2017 Jul 1;65(1):141-146. doi: 10.1093/cid/cix246. Clin Infect Dis. 2017. PMID: 29017263 Free PMC article. Review.

6

Phase 2 study of ceftaroline versus standard therapy in treatment of complicated skin and skin structure infections.

Talbot GH, Thye D, Das A, Ge Y. Talbot GH, et al. Antimicrob Agents Chemother. 2007 Oct;51(10):3612-6. doi: 10.1128/AAC.00590-07. Epub 2007 Aug 6. Antimicrob Agents Chemother. 2007. PMID: 17682094 Free PMC article. Clinical Trial.

7

Safety and efficacy of quinupristin/dalfopristin for treatment of invasive Gram-positive infections in pediatric patients.

Loeffler AM, Drew RH, Perfect JR, Grethe NI, Stephens JW, Gray SL, Talbot GH. Loeffler AM, et al. Among authors: talbot gh. Pediatr Infect Dis J. 2002 Oct;21(10):950-6. doi: 10.1097/00006454-200210000-00013. Pediatr Infect Dis J. 2002. PMID: 12394819

8

β-Lactam antimicrobials: what have you done for me lately?

Talbot GH. Talbot GH. Ann N Y Acad Sci. 2013 Jan;1277:76-83. doi: 10.1111/j.1749-6632.2012.06809.x. Epub 2012 Nov 29. Ann N Y Acad Sci. 2013. PMID: 23346858 Review.

9

Prospective study of the Wilson severity-of-illness scoring system for complicated skin and skin structure infections.

Talbot GH, O'Neal T, Das AF, Thye D. Talbot GH, et al. Antimicrob Agents Chemother. 2013 Jan;57(1):647-50. doi: 10.1128/AAC.01344-12. Epub 2012 Nov 5. Antimicrob Agents Chemother. 2013. PMID: 23129046 Free PMC article.

10

Macrolide therapy for community-acquired pneumonia due to atypical pathogens: outcome assessment at an early time point.

File TM Jr, Eckburg PB, Talbot GH, Llorens L, Friedland HD. File TM Jr, et al. Among authors: talbot gh. Int J Antimicrob Agents. 2017 Aug;50(2):247-251. doi: 10.1016/j.ijantimicag.2017.01.043. Epub 2017 Jun 6. Int J Antimicrob Agents. 2017. PMID: 28599867

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

125 results

Search Page

Filters